FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286203169> ?p ?o ?g. }

• W4286203169 endingPage "8037" @default.
• W4286203169 startingPage "8037" @default.
• W4286203169 abstract "Prostate specific membrane antigen targeted radionuclide therapy (PSMA-TRT) is a promising novel treatment for prostate cancer (PCa) patients. However, PSMA-TRT cannot be used for curative intent yet, thus additional research on how to improve the therapeutic efficacy is warranted. A potential way of achieving this, is combining TRT with poly ADP-ribosylation inhibitors (PARPi), which has shown promising results for TRT of neuroendocrine tumor cells. Currently, several clinical trials have been initiated for this combination for PCa, however so far, no evidence of synergism is available for PCa. Therefore, we evaluated the combination of PSMA-TRT with three classes of PARPi in preclinical PCa models. In vitro viability and survival assays were performed using PSMA-expressing PCa cell lines PC3-PIP and LNCaP to assess the effect of increasing concentrations of PARPi veliparib, olaparib or talazoparib in combination with PSMA-TRT compared to single PARPi treatment. Next, DNA damage analyses were performed by quantifying the number of DNA breaks by immunofluorescent stainings. Lastly, the potential of the combination treatments was studied in vivo in mice bearing PC3-PIP xenografts. Our results show that combining PSMA-TRT with PARPi did not synergistically affect the in vitro clonogenic survival or cell viability. DNA-damage analysis revealed only a significant increase in DNA breaks when combining PSMA-TRT with veliparib and not in the other combination treatments. Moreover, PSMA-TRT with PARPi treatment did not improve tumor control compared to PSMA-TRT monotherapy. Overall, the data presented do not support the assumption that combining PSMA-TRT with PARPi leads to a synergistic antitumor effect in PCa. These results underline that extensive preclinical research using various PCa models is imperative to validate the applicability of the combination strategy for PCa, as it is for other cancer types." @default.
• W4286203169 created "2022-07-21" @default.
• W4286203169 creator A5002755456 @default.
• W4286203169 creator A5010797456 @default.
• W4286203169 creator A5011219611 @default.
• W4286203169 creator A5013114658 @default.
• W4286203169 creator A5030576082 @default.
• W4286203169 creator A5038742233 @default.
• W4286203169 creator A5040369608 @default.
• W4286203169 creator A5066411163 @default.
• W4286203169 creator A5070230556 @default.
• W4286203169 creator A5078854582 @default.
• W4286203169 date "2022-07-21" @default.
• W4286203169 modified "2023-10-17" @default.
• W4286203169 title "Preclinical Assessment of the Combination of PSMA-Targeting Radionuclide Therapy with PARP Inhibitors for Prostate Cancer Treatment" @default.
• W4286203169 cites W1906457741 @default.
• W4286203169 cites W1967700496 @default.
• W4286203169 cites W2061404903 @default.
• W4286203169 cites W2082618949 @default.
• W4286203169 cites W2095798342 @default.
• W4286203169 cites W2112241575 @default.
• W4286203169 cites W2118122348 @default.
• W4286203169 cites W2343936933 @default.
• W4286203169 cites W2514976083 @default.
• W4286203169 cites W2784080506 @default.
• W4286203169 cites W2805227228 @default.
• W4286203169 cites W2884314425 @default.
• W4286203169 cites W2889740932 @default.
• W4286203169 cites W2900633622 @default.
• W4286203169 cites W2906986535 @default.
• W4286203169 cites W2947948130 @default.
• W4286203169 cites W2981004493 @default.
• W4286203169 cites W2996357887 @default.
• W4286203169 cites W3005930092 @default.
• W4286203169 cites W3014627414 @default.
• W4286203169 cites W3015310737 @default.
• W4286203169 cites W3018583760 @default.
• W4286203169 cites W3029012726 @default.
• W4286203169 cites W3036666213 @default.
• W4286203169 cites W3040484495 @default.
• W4286203169 cites W3082336972 @default.
• W4286203169 cites W3159905079 @default.
• W4286203169 cites W3176208875 @default.
• W4286203169 cites W4214739476 @default.
• W4286203169 doi "https://doi.org/10.3390/ijms23148037" @default.
• W4286203169 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35887398" @default.
• W4286203169 hasPublicationYear "2022" @default.
• W4286203169 type Work @default.
• W4286203169 citedByCount "8" @default.
• W4286203169 countsByYear W42862031692022 @default.
• W4286203169 countsByYear W42862031692023 @default.
• W4286203169 crossrefType "journal-article" @default.
• W4286203169 hasAuthorship W4286203169A5002755456 @default.
• W4286203169 hasAuthorship W4286203169A5010797456 @default.
• W4286203169 hasAuthorship W4286203169A5011219611 @default.
• W4286203169 hasAuthorship W4286203169A5013114658 @default.
• W4286203169 hasAuthorship W4286203169A5030576082 @default.
• W4286203169 hasAuthorship W4286203169A5038742233 @default.
• W4286203169 hasAuthorship W4286203169A5040369608 @default.
• W4286203169 hasAuthorship W4286203169A5066411163 @default.
• W4286203169 hasAuthorship W4286203169A5070230556 @default.
• W4286203169 hasAuthorship W4286203169A5078854582 @default.
• W4286203169 hasBestOaLocation W42862031691 @default.
• W4286203169 hasConcept C117262875 @default.
• W4286203169 hasConcept C121608353 @default.
• W4286203169 hasConcept C126322002 @default.
• W4286203169 hasConcept C143998085 @default.
• W4286203169 hasConcept C150903083 @default.
• W4286203169 hasConcept C182979987 @default.
• W4286203169 hasConcept C185592680 @default.
• W4286203169 hasConcept C20417620 @default.
• W4286203169 hasConcept C207001950 @default.
• W4286203169 hasConcept C2776999253 @default.
• W4286203169 hasConcept C2779138821 @default.
• W4286203169 hasConcept C2779723316 @default.
• W4286203169 hasConcept C2779962180 @default.
• W4286203169 hasConcept C2780192828 @default.
• W4286203169 hasConcept C2781312401 @default.
• W4286203169 hasConcept C2993559085 @default.
• W4286203169 hasConcept C502942594 @default.
• W4286203169 hasConcept C552990157 @default.
• W4286203169 hasConcept C55493867 @default.
• W4286203169 hasConcept C71924100 @default.
• W4286203169 hasConcept C82381507 @default.
• W4286203169 hasConcept C86803240 @default.
• W4286203169 hasConceptScore W4286203169C117262875 @default.
• W4286203169 hasConceptScore W4286203169C121608353 @default.
• W4286203169 hasConceptScore W4286203169C126322002 @default.
• W4286203169 hasConceptScore W4286203169C143998085 @default.
• W4286203169 hasConceptScore W4286203169C150903083 @default.
• W4286203169 hasConceptScore W4286203169C182979987 @default.
• W4286203169 hasConceptScore W4286203169C185592680 @default.
• W4286203169 hasConceptScore W4286203169C20417620 @default.
• W4286203169 hasConceptScore W4286203169C207001950 @default.
• W4286203169 hasConceptScore W4286203169C2776999253 @default.
• W4286203169 hasConceptScore W4286203169C2779138821 @default.
• W4286203169 hasConceptScore W4286203169C2779723316 @default.
• W4286203169 hasConceptScore W4286203169C2779962180 @default.

• next